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Age Related Differences in 
Responsiveness to Sildenafil and 
Tamsulosin are due to Myogenic 
Smooth Muscle Tone in the Human 
Prostate
Sophie N. Lee2, Basu Chakrabarty1, Brad Wittmer1,2, Melissa Papargiris2, Andrew Ryan3,  
Mark Frydenberg4,5, Nathan Lawrentschuk  6, Ralf Middendorff7, Gail P. Risbridger2,  
Stuart J. Ellem2 & Betty Exintaris1
Lower urinary tract symptoms (LUTS) due to Benign Prostatic Hyperplasia (BPH) are highly prevalent 
in older men, having a profound impact on patient quality of life. Current therapeutics for BPH/
LUTS target neurogenic smooth muscle tone, but response is unpredictable and many patients fail 
to respond. Spontaneous myogenic tone is another component of smooth muscle contractility that 
is uncharacterized in human prostate. To better understand and improve the predictability of patient 
response, we defined myogenic contractility using human prostate specimens and examined the 
effect of existing therapeutics. We show that myogenic activity is present in the human prostate 
with the frequency of contractions in transition zone (TZ) specimens from BPH diagnosed patients 
approximately 160% greater than matched controls. α1-adrenoreceptor antagonists (Tamsulosin) 
and PDE5 inhibitors (Sildenafil) both significantly reduced myogenic contractile parameters, including 
frequency, with notable interpatient variability. Tamsulosin was more effective in older patients 
(R2 = 0.36, p < 0.01) and men with larger prostate volumes (R2 = 0.41, p < 0.05), while Sildenafil was 
more effective in younger men (R2 = 0.45, p < 0.05). As myogenic tone is significantly increased in BPH, 
therapeutics targeting this mechanism used with reference to patient characteristics could improve 
clinical outcomes and better predict patient response.
Benign Prostatic Hyperplasia (BPH) is a complex, non-malignant, and highly prevalent disease that affects ageing 
men1. This disease affects 50% of men over 50 and 90% of men over 80, resulting in severe lower urinary tract 
symptoms (LUTS) that have an enormous impact on a patients quality of life2. This problem is compounded by 
the aging population3, and is further exacerbated by the limited efficacy of current front-line therapeutics and the 
unpredictable nature of patient response to these drugs. Consequently, there is an urgent need to better under-
stand the physiology and etiology of BPH in order to improve patient treatment and outcome4.
There are two distinct components that underlie the etiology of BPH, a static and a dynamic compo-
nent5. The static component consists of stromal hyperplasia or hypertrophy, leading to an increased pros-
tate size. The dynamic component is characterized by changes in smooth muscle contractility, notably tone. 
Pharmacotherapies targeting smooth muscle tone, notably α1A-adrenoreceptor antagonists (alpha blockers)4 and 
Phosphodiesterase-5 inhibitors (PDE5-Is), are currently used for the treatment of BPH and alleviation of LUTS. 
However, both pharmacotherapies are limited due to their unpredictable efficacy in a given patient, insufficient 
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relief of symptoms, and adverse side-effects6, 7. A retrospective analysis into the discontinuation of alpha block-
ers found that of an initial study population of 13,474 men, 47.1% terminated treatment within the first year, 
with only 30.1% of men compliant with treatment after 12 months8. Phosphodiesterase-5 inhibitors (PDE5-Is) 
promote smooth muscle relaxation through blocking the degradation of cGMP, and were proposed as a therapy 
for BPH in 2007 after men with erectile dysfunction reported relief of BPH symptoms while on PDE5-Is9, 10. 
Preclinical data indicates that PDE5-Is act on the lower urinary tract at multiple sites and via multiple mecha-
nisms7, although a definitive mechanism of action in the human prostate has yet to be elucidated.
Smooth muscle tone specifically refers to the sustained state of contraction within a muscle and can be further 
separated into neurogenic and myogenic components11. Neurogenic tone has been well described in the human 
prostate, and is mediated by release of neurotransmitters from the autonomic nervous system, notably during 
ejaculation12. Myogenic tone is the inherent and spontaneous rhythmicity of the tissue, which is mediated inde-
pendently of stimulus from the autonomic nervous system. Myogenic tone is well characterized in other lower 
urinary tract organs, notably the bladder13, where overactive bladder (OAB) is now recognized to be driven by 
changes in myogenic contractility14, and several therapies have been developed to target this15. Despite extensive 
characterization of neurogenic contractility of the prostate, the myogenic tone of the human prostate has yet to 
be characterized.
In this study we demonstrate that myogenic tone is present in the human prostate by utilizing primary pros-
tate specimens from a clinically diverse cohort of men. We show that the frequency of myogenic tone is signifi-
cantly increased in men with clinical/symptomatic BPH. Both existing (alpha blockers; tamsulosin) and emerging 
(PDE5-Is; sildenafil) therapeutics attenuated myogenic tone, with interpatient variability in responsiveness signif-
icantly correlated with age and prostate volume. Importantly, these data also show that clinical parameters could 
be used to predict efficacy and thus improve patient response and outcome.
Results
Spontaneous myogenic tone exists in the human prostate and is significantly different in 
Transition versus Peripheral zones. Tension recordings were used to assess myogenic contractility in 
patient TZ and PZ tissue specimens (Fig. 1A and B, representative traces from TZ and PZ tissues from the same 
individual patient). TZ specimens demonstrated a higher basal tension (Fig. 1C) compared to PZ tissues, while 
the amplitude (Fig. 1D) and frequency of contractions (Fig. 1E) were significantly greater in PZ specimens. The 
difference in contractility between the zonal regions was associated with differences in tissue composition that 
is evident in the pathology of matched TZ and PZ specimens from the same patients. Azan trichrome staining 
showed zonal differences in the distribution of glands and smooth muscle cells within the stroma (Fig. 1F), and 
increased fibrosis in TZ tissue (Fig. 1G). Sections stained for α-SMA (Fig. 1F), revealed that PZ tissue possesses a 
significantly greater number of α-SMA positive cells than patient-matched TZ specimens (Fig. 1H). Application 
of blockers of neural transmitters, Tetrodotoxin (TTX; 1 µM, n = 5) or Atropine (1 µM, n = 6), did not have any 
effect on myogenic contractile parameters (Supplementary Figure 1).
Myogenic tone is significantly greater in the transition zone of men with clinically diagnosed 
BPH. We established a clinically diverse cohort of tissues from 38 men (details in Table 1). Within this cohort, 
there was a subset of 13 patients who had clinical BPH associated with LUTS (Fig. 2A and E) that was retrospec-
tively identified from clinical records. This subgroup was used to test if myogenic tone is altered in TZ tissue 
from men with BPH. We compared tension recordings of myogenic contractions in tissue from the men with 
clinical BPH to age-matched (similar age ± 2 years, not receiving pharmacotherapy at the time of prostatectomy, 
prostate volume ≤40cc; Fig. 2A–D), or to prostate volume-matched controls (similar prostate volume ± 5cc, not 
receiving pharmacotherapy at the time of prostatectomy; Fig. 2E–H). Four (4) men from the BPH cohort were 
excluded from analysis based on a Grubb’s test, and previous treatment with pharmacotherapies, resulting in the 
BPH cohort consisting of n = 9. The frequency of myogenic contractions was significantly (p < 0.05) greater in TZ 
specimens collected from men with clinically diagnosed BPH when compared to both age (Fig. 2D) and prostate 
volume-matched (Fig. 2H) controls. The frequency of contractions in BPH diagnosed patients was 157.63% and 
171.97% greater than age and prostate volume-matched controls, respectively. Basal tension and amplitude of 
contractions was not significantly different in men with BPH when compared to age (Fig. 2B and C) or volume 
(Fig. 2F and G) matched controls. Overall these results show the frequency of myogenic contractions is greater 
in men with BPH.
Tamsulosin attenuates myogenic contractility in the human prostate with responsiveness cor-
relating to older patients and larger prostate volumes. To determine if current therapies for BPH 
modulate myogenic tone we tested the response to α1A-adrenoreceptor antagonist Tamsulosin in vitro in an 
organ bath model system. Tamsulosin (0.1 nM) significantly reduced the basal tension, amplitude and frequency 
of myogenic contractions in TZ specimens following incubation for 30 minutes (Fig. 3A,B and C, respectively; 
representative trace Fig. 3D and E). Regression analysis was performed using clinical parameters obtained from 
retrospective analysis of patient details against the percentage of the control activity (% control), with 0% indi-
cating complete abolishment of contractile activity, and 100% indicating contractility remained unchanged fol-
lowing treatment (Fig. 3F). Age and prostate volume both significantly (P < 0.05) negatively correlated with the 
% control change in the amplitude of contractions (Fig. 3G and H, respectively). Overall, demonstrating a greater 
efficacy of Tamsulosin at reducing myogenic activity in older men and/or those with larger prostate volumes.
Sildenafil decreases myogenic contractility with responsiveness significantly correlated to 
younger patients. PDE5-Is appear to reduce LUTS secondary to BPH, although the mechanism of action 
in the prostate is unclear. To test if the PDE5-I Sildenafil altered myogenic contractility we conducted similar in 
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Figure 1. Myogenic contractility is significantly different in Transition versus Peripheral zones of the human 
prostate. Representative traces of spontaneous activity in the (A) Transition Zone and (B) Peripheral Zone, 
and the average (C) resting basal tension, (D) amplitude, and (E) frequency of spontaneous contractions in 
the transition zone in comparison to the peripheral zone of matched patients (Student’s paired t-test, n = 10, * 
indicates p < 0.05, ** indicates p < 0.01). (F) representative images of I) & II) Azan Trichrome Staining and III) 
& IV) α-Smooth Muscle Actin (α-SMA) from the I) & III) Peripheral and II) & IV) Transition zone of a same 
matched patient. (G) Percent of positive stromal pixels corresponding to strong collagen staining in sections 
stained with Azan Trichrome (Student’s paired t-test. N = 4, **indicates p < 0.01) (H) Percentage of positive 
staining for α-SMA to the total stromal area (Student’s paired t-test. N = 4, **indicates p < 0.01).
Demographic Number (% of cohort) Mean (±SD) Range
Total Patients 38 (100%)
Clinical BPH 
Diagnosis 13 (34.2)
LUTS reported 16 (42.1)
LUTS and BPH 8 (21.1)
Age 65.5 (6.6) 50–77
Prostate Volume (cc) 44.7 (22.0) 12–144
Gleason Score 7 (N/A) 6–9
Table 1. Characteristics of the BPH Patient Cohort.
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vitro organ bath studies. Sildenafil (10 µM) significantly decreased the basal tension and frequency of myogenic 
contractions in TZ specimens following incubation for 30 minutes, while amplitude was unaffected (Fig. 4A–C; 
representative traces Fig. 4D and E). There was a large interpatient variability associated with the decrease in 
frequency in response to Sildenafil, with the % control ranging from 10.2–122.2% (Fig. 4F). Regression analysis 
was used to compare % control of the frequency of contractions with age and demonstrated overall a significant 
positive correlation between % control and age (Fig. 4G).
Immunohistochemistry was conducted to assess the presence and distribution of PDE5. PDE5 expression was 
observed within the stroma, but not the epithelium (Supplementary Figure 1). In 80% (4/5) patients, there was 
also higher expression of PDE5 in the TZ compared to patient matched PZ specimens when semi-quantitatively 
assessed (Supplementary Figure 1). PKG-1, a downstream protein of the cGMP signalling pathway and the most 
important protein involved in relaxation, was also assessed as a positive internal control for cGMP pathway 
expression. PKG-1 was strongly expressed in the stroma, with no epithelial staining. There was also extremely 
high expression of PKG-1 in the vasculature of the prostate, whereas PDE5 expression in vessels was lower 
(Supplementary Figure 2). Importantly, this vascular localization of PDE5/PKG1 is well known for other tissues 
and peripheral blood vessels do not contract spontaneously, thus the PDE5 expression in prostatic vessels cannot 
influence the contractility observed in our organ bath studies. Collectively, these data highlight the potential of 
PDE5-Is to alleviate LUTS, particularly in younger patients.
Discussion
Our study is the first to describe and characterize spontaneous myogenic contractility in the human prostate 
gland. Using a cohort of 38 men we show that the frequency of myogenic contractions is increased in men with 
clinical BPH. Additionally, we also show that the features of myogenic tone can be selectively attenuated by two 
current BPH therapeutics, Tamsulosin and Sildenafil. Although there is substantial interpatient variability, the 
response to Tamsulosin and Sildenafil is correlated with specific patient parameters (age, prostate volume).
These novel findings have significant implications for improving patient outcomes for BPH similar to what has 
occurred in the bladder. Since the initial observation by Brading and colleagues that there is a myogenic basis for 
the overactive bladder13 there has been a significant shift in the field of bladder research into understanding the 
mechanisms underlying myogenic tone in bladder contractility, and developing therapeutics targeting this com-
ponent. The myogenic hypothesis is a current rationale for the pathophysiology of overactive bladder disease16. 
Figure 2. The frequency of myogenic contractions is significantly higher in Transition Zone specimens from 
men with BPH compared to age and volume matched controls. Frequency distribution histograms of BPH 
diagnosed men within the patient cohort by (A) Age and (B) Prostate Volume. The average (C,F) basal tension 
(mN), (D,G) amplitude and (D,H) frequency of spontaneous contractions within the TZ of men with clinically 
diagnosed BPH compared to age (B,C,D) and prostate volume (F,G,H) matched controls (Student’s unpaired 
t-test, n = 9, * indicates p < 0.05, *** indicates p < 0.001).
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Recently, Botulinum toxin A (BoNT-A) was described as attenuating myogenic contractions of the rat bladder17, 
and is currently used as a treatment for overactive bladder and detrusor overactivity18. We now demonstrate that 
human prostate contractility also possesses a myogenic component. The myogenic origin of the contractions 
is evident as application of TTX (which prevent the release of neurotransmitters from the synaptic cleft on the 
neuronal axon terminal19) or Atropine (a Muscarinic Receptor antagonist), did not attenuate any of the myogenic 
contractile parameters. Therefore, these contractions are of a myogenic, not neurogenic, origin.
BPH arises in the TZ of the human prostate, and we found that the frequency of myogenic contractions 
in the TZ was significantly higher in men with clinically diagnosed BPH when compared to both age and 
prostate-volume matched controls. Prostatic smooth muscle vigorously contracts during ejaculation in order 
to expel prostatic fluids from the glands of the prostate into the ejaculate12. This is regulated by the Sympathetic 
Nervous System (SNS), which releases noradrenaline acting on α1-adrenoreceptors to generate the neurogenic 
contraction. α1-adrenoreceptors are the predominant SNS receptor within the human prostate20, and have ele-
vated expression in BPH diagnosed men21, 22. Consequently, alpha blockers (e.g Tamsulosin) have been one of the 
mainstay therapies for BPH for decades, although they have unpredictable efficacy, and are associated with unde-
sirable side effects4. Myogenic tone is fundamentally different in that contractions are generated independently of 
stimulus from the SNS, occur consistently, and are of a smaller magnitude. As the frequency of these contractions 
is upregulated in men with clinically diagnosed BPH, we hypothesize that an ideal pharmacotherapy will target 
both neurogenic and myogenic tone. Significantly, we found that Tamsulosin diminished myogenic activity in 
TZ, with a reduction in all parameters (basal tension, amplitude and frequency). Further, subsequent regression 
analysis revealed an association between specific clinical parameters and the response to Tamsulosin in terms of 
amplitude and frequency. Specifically, older patients, or patients with larger prostate volumes, demonstrated a 
greater reduction in the amplitude of myogenic contractions in response to Tamsulosin. Along with the increased 
density of α1-adrenoreceptors in the human prostate with age23, our data provide further rationale for the use 
of α1-adrenoreceptor antagonists specifically in older men (>70 years), or those with larger prostates (>40cc).
Figure 3. Tamsulosin (10−10M) decreases myogenic contractility in Transition Zone specimens, with larger 
response correlating to increased age and prostate volume. (A) Basal tension, (B) amplitude, and (C) frequency 
of contractions pre and post tamsulosin (0.1 nM) (Student’s paired t-test, n = 15, * indicates p < 0.05, ** 
indicates p < 0.01, *** indicates p < 0.001), (D) representative trace showing pre-treatment control activity 
and (E) representative trace showing treatment response. (F) Contractile Parameters following administration 
of Tamsulosin were converted to a percentage of the original (untreated) contractile parameters. Correlation 
between (G) age and (H) prostate volume and percentage decrease in amplitude of spontaneous contractions 
(Linear Regression Analysis, p < 0.05 considered significant).
www.nature.com/scientificreports/
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PDE5 inhibitors were recently approved for the treatment of BPH, and are included in the guidelines from 
both the AUA and EAU regarding therapeutics for the treatment of this disease4, 24. Initially used to treat erectile 
dysfunction, there is little evidence of the mechanism of action on the human prostate gland24 although patients 
reported significant reductions in IPSS score25. Our in vitro studies show a direct effect of Sildenafil, significantly 
reducing basal tension and frequency of myogenic contractions. The decrease in frequency was variable between 
patients but was inversely correlated with patient age and older patients (>70) demonstrated little to no response 
to Sildenafil. This observation is supported by a recent meta-analysis that found older patients experienced lim-
ited improvement in IPSS scores with PDE5-Is compared to younger men25, as well as the observed PDE5 expres-
sion levels in prostate tissue, which was higher in younger patients (Supplementary Figure 1). Collectively these 
data suggest that the use of PDE5 inhibitors for BPH is more suited to younger men.
One of the major challenges with a study of this type is obtaining viable primary human prostate tissue for 
tension recordings. Transurethral Resection of the Prostate (TURP) is the most common surgical procedure for 
men with BPH. However the tissue is unsuitable for investigation for two reasons. Firstly, TURP is commonly 
performed after treatment failure and cannot provide treatment naïve specimens. Secondly, the tissue is fre-
quently physically damaged in the process, rendering it unable to be used for subsequent studies. We overcame 
these issues by obtaining tissue from men undergoing radical prostatectomy for localised prostate cancer and 
from their clinical records we identified men with LUTS and clinical BPH. We used tissue from patients with low 
volume tumours in PZ from whom we could obtain TZ tissues for investigation. This approach, however, limits 
clinical details regarding LUTS and BPH symptomology, with only two patients in the cohort completing the IPSS 
questionnaire prior to surgery.
Overall, BPH is an extremely prevalent disease with a high economic and social impact. Current therapeutics 
lack overall and consistent efficacy, while predicting patient response is currently impossible. Our study provides 
evidence that myogenic (spontaneous) activity is associated with BPH within the human prostate. Frequency of 
myogenic contractions is elevated in men with BPH, and is diminished using current therapeutics (Tamsulosin 
Figure 4. Sildenafil (10−5 M) significantly decreases basal tension and frequency of myogenic contractility 
within the human prostate Transition Zone. (A) Basal tension, (B) amplitude, and (C) frequency of contractions 
pre and post sildenafil (10 µM) (Student’s paired t-test, n = 12, * indicates p < 0.05, ** indicates p < 0.01), (D) 
representative trace showing pre-treatment control activity and (E) representative trace showing treatment 
response. (F) Contractile Parameters following administration of sildenafil were converted to a percentage of 
the original (untreated) contractile parameters. Correlation between (G) age and percentage decrease of the 
frequency of spontaneous contractions (Linear Regression Analysis, p < 0.05 considered significant).
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and Sildenafil). Importantly, this response significantly correlated with patient age and prostate volume, with 
Tamsulosin demonstrating greater efficacy in tissues from older men and those with larger prostate volumes, 
while Sildenafil was most effective in tissues from younger men. Collectively, these data highlight that therapeu-
tics that modulate myogenic tone, when applied based on patient characteristics such as age, may yield improved 
and predictable clinical outcomes for patients with BPH.
Materials and Methods
Patient Cohort. Human prostatic tissue was collected with informed written consent from patients and 
approval from the Cabrini Human Research Ethics Committee (13-14-04-08), Epworth HealthCare Human 
Ethics Committee (53611) and Monash University Human Research Ethics Committee (2004/145). All experi-
ments were performed in accordance with relevant guidelines and regulations. Tissue was collected from 38 men 
undergoing radical prostatectomy for the treatment of low to medium grade prostatic cancer (Gleason Score ≤ 
7). A rigorous tissue selection procedure was employed to minimize any possible influence of the tumour on the 
non-malignant tissue. Only patients with a single tumour foci located in the PZ were selected, and, secondly, only 
those with a very low tumour volume as a percentage of the prostate weight (under 10%) were utilized. Patient 
clinical details are shown in Table 1.
Following prostatectomy, pieces of non-malignant prostatic tissue were cut from the transition (TZ) and peripheral 
(PZ) zone of the prostate by a certified pathologist, and placed in chilled Physiological Saline Solution (PSS) for trans-
portation to the research facilities. Tissue was prepared by micro-dissection into preparations (2mm × 5mm) for organ 
bath studies, or fixed in formalin (10%) for histological analysis. Patient clinical records were retrospectively accessed 
through physicians, hospitals, and diagnostic laboratories. Clinical BPH was diagnosed by the surgeons prior to radical 
prostatectomy, and was defined based on the grade of Intravesical Prostatic Protrusion (IPP), and the presence of LUTS. 
Patients with prior pharmacological treatment for BPH were excluded from the cohort.
Organ Bath Studies. Tension recordings were obtained from TZ and PZ specimens as previously 
described26–28. An initial tension of 25mN was applied to the tissue, and left to equilibrate for 60 minutes. The ‘basal 
tension’ describes the tension of the tissue following this equilibration period. This tension was not re-adjusted 
to a predefined baseline to allow spontaneous contractions to emerge. Following the equilibration period, the 
preparation was incubated with either Tamsulosin (0.1 nM), Sildenafil (10 μM), Atropine (1 µM) or tetrodotoxin 
(TTX:1 µM), prepared in fresh Physiological Saline Solution (PSS), for a period of 30 minutes (see supplementary 
methods for details of all chemicals and reagents). Following a washout period, the tissue was challenged with a 
potassium chloride solution (20 mM) to assess tissue viability and reliably induces a robust contraction in all viable 
preparations. Preparations were subsequently weighed following the completion of experiments.
Analysis of tension recordings focused on three parameters: basal tension (the inherent tension within the 
tissue; mN), as well as amplitude and frequency (strength and speed of contractions; N/g and min−1, respectively) 
as previously reported26, 29. These parameters are as used in previous studies to define myogenic tone26–28. Chart 
Pro ® v 5.5.6 was used to analyse the tension recordings, with indicated parameters measured for 5 consecutive 
responses and averaged before and during incubation with Tamsulosin (0.1 nM) or Sildenafil (10 μM).
Immunohistochemistry and tissue stains. Sections were de-paraffinised and rehydrated through a 
series of xylene and graded ethanol solutions. Sections were placed in 1.2% H2O2 for 30 minutes to block endog-
enous peroxidase activity, and were incubated with the primary antibodies; PKG-1 (1:1000, ADI-KAP-PK005-F, 
Enzo Life Sciences), PDE5A (1:500, FabGennix) and α-Smooth Muscle Actin (α-SMA) (1:10,000, Sigma), diluted 
in PBS with 0.2% BSA and 0.1% sodium azide for 24 hours at 4 °C. Immunoreactivity was visualized using the 
DAKO EnVision kit (DAKO, Hamburg, Germany) followed by the nickel-glucose oxidase approach30. Antigen 
retrieval was performed prior to incubation with the primary antibody for sections incubated with the α-SMA 
and PDE5A antibody by boiling citrate-buffer (pH 6.0) in a microwave (9 minutes at 700 W followed by 15 min-
utes at 450 W). Negative controls were performed by omitting the primary antibody.
Slides were scanned using an Aperio ScanScope scanner and Aperio ImageScope software was used to visu-
alize and define stromal regions of the tissue, excluding glandular regions. The Aperio Color Deconvolution v9 
algorithm was used to quantify the percent of positive pixels corresponding to strong collagen staining, while the 
Positive Pixel Count v9 algorithm with default parameters was used to determine α-SMA cell counts. Blinded 
studies were conducted using three (3) naïve viewers, who were instructed to score the intensity of staining using 
the following criteria; (−) no staining, (+) low staining, and (++) high staining.
Chemicals and Reagents. Physiological saline solution (PSS) was composed of 2.5 mM CaCl2, 11 mM 
D-Glucose, 5 mM KCl, 120 mM NaCl, 25 mM NaHCO3, 1.2 mM KH2PO4, 1.2 mM MgSO4, bubbled with a 95% 
O2: 5% CO2 gas mixture to maintain a pH of 7.3-7.4. Sildenafil (Sigma, St Louis, MO, USA) was dissolved in dime-
thyl sulfoxide (DMSO, Sigma, St Louis, MO, USA) to create a stock solution (10 mM). Tamsulosin (Yamanouchi 
Pharmaceutical Co. Ltd, Tokyo, Japan; gift from Assoc. Prof. J. N. Pennefather) was dissolved in distilled water to 
create a stock solution (0.01 mM). Stock solution was diluted in PSS to the required concentrations and bubbled 
with a 95% O2: 5% CO2 gas mixture prior to use.
Statistical Analysis. Patient-matched TZ and PZ specimens were compared using a Student’s paired t-test. 
Student’s unpaired t-tests were used to compare contractile parameters between groups of men within the cohort. 
Treatment with a single pharmacotherapy was compared using a Student’s paired t-test with GraphPad Prism 
version 6.04 for Windows (GraphPad Software, La Jolla California USA). An Extreme Studentized Deviate (ESD) 
test with an Alpha level of 0.05 was used to exclude outliers. Multi-linear regression analysis was used to corre-
late clinical records with the percentage response to pharmacotherapy treatment using IBM SPSS Statistics for 
Windows, Version 22.0. All error bars on all graphs represent the Standard Error of the Mean (SEM).
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